

P&T Motion History Multiple Sclerosis Drugs

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
alemtuzumab cladribine dimethyl fumarate diroximel fumarate fingolimod glatiramer acetate interferon β 1a IM, SC interferon β 1b SC monomethyl fumarate peginterferon β 1a SC ocrelizumab ofatumumab ozanimod ponesimod siponimod teriflunomide ublituximab daclizumab HYP* mitoxantrone* natalizumab*	After considering the evidence of safety, efficacy and special populations for the treatment of Multiple Sclerosis, I move that alemtuzumab, cladribine, dimethyl fumarate, diroximel fumarate, fingolimod, glatiramer acetate, interferon β 1a IM, interferon β 1a SC, interferon beta 1b SC, monomethyl fumarate, peginterferon β 1a SC, ocrelizumab, ofatumumab, ozanimod, ponesimod, Siponimod, teriflunomide, and ublituximab are safe and efficacious. A product that is safe for use during pregnancy should be made available. The MS Drugs cannot be subject to therapeutic interchange in the Washington preferred drug list for the treatment of Multiple Sclerosis. An oral agent should be included in the list of preferred drugs on the PDL. Motion: Beste 2nd: Flynn	October 15, 2025	Yes Motion: Park 2 nd : Barkett	N/A	Passed unanimous

Bold = new this update

Grey = not reviewed by OHSU and therefore, not eligible to be preferred

*=drugs not reviewed, but carried forward from previous review

10/23/2025